Skip to main
  1. Stocks
  2. Natera
  3. Forecast
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Natera is favored because its dominant >90% share in a $15B+ MRD market gives it a durable competitive moat, supported by strong reimbursement coverage, growing clinical adoption, and management’s track record of upward revisions. Signatera remains the key earnings engine, with ~60% volume growth in 2025, a current ASP of $1,275 versus a $3,590 Medicare rate, and a credible path toward 70%+ gross margin and 25%+ EBIT over time as COGS have already fallen more than $100 since 2022. The outlook is further strengthened by pipeline catalysts in ultra-sensitive Signatera Genome, pharma data monetization, and early cancer detection, where management sees roughly $1.5B of incremental revenue potential from colorectal screening alone.

Bears say

Natera is viewed negatively because its growth story depends heavily on MRD adoption, yet penetration in established uses like CRC adjuvant already exceeds 50%, limiting incremental upside while expansion into other cancers may stall. Competitive pressures are intensifying across MRD and Women’s Health, and the company’s catalysts have been inconsistent, with delayed guideline updates, failed trials, and reliance on factors outside management’s control. Although MRD ASPs have risen from roughly $500 to $1,250 over the past five years, further progress toward $2,000 may not be linear, leaving revenue and margin assumptions vulnerable if reimbursement or share gains slow.

Natera (NTRA) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Natera (NTRA) Analyst Forecast & Price Prediction

Get the latest Natera (NTRA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Natera (NTRA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 19 analysts, Natera (NTRA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $398.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $398.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Natera (NTRA) Analyst Forecast & Price Prediction

Get the latest Natera (NTRA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Natera (NTRA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NTRA stock data and trends